Claims for Patent: 10,426,832

Summary for Patent: 10,426,832

Title:	Liquid pharmaceutical composition
Abstract:	The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabilizer such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
Inventor(s):	Rinaldi; Gianluca (Monterotondo, IT), Fratarcangeli; Silvia (Ceprano, IT), Del Rio; Alessandra (Rome, IT)
Assignee:	FRESENIUS KABI DEUTSCHLAND GMBH (Bad Homburg, DE)
Application Number:	15/313,470
Patent Claims:	1. An aqueous pharmaceutical composition comprising: (a) 45-55 mg/mL adalimumab; (b) 5-14 mM acetate buffering agent or acetate buffer system; (c) 190-300 mM sugar stabilizer consisting of sucrose; and (d) 0.9-1.1 mg/mL polysorbate 80; wherein the composition: has a pH between 5.1 and 5.3; is free of arginine; is free of phosphate buffering agents; is free of amino acids; is free of surfactants, with the exception of polysorbate 80; and comprises at most one sugar stabilizer. 2. The aqueous pharmaceutical composition of claim 1, wherein the composition comprises the sugar stabilizer sucrose at a concentration of 250 to 300 mM. 3. The aqueous pharmaceutical composition of claim 1, wherein the composition comprises the acetate buffering agent or acetate buffer system at a concentration of 10 mM. 4. The aqueous pharmaceutical composition of claim 3, wherein the acetate buffering agent or acetate buffer system comprises sodium acetate. 5. The aqueous pharmaceutical composition of claim 1, wherein the composition comprises the adalimumab at a concentration of 50 mg/mL. 6. The aqueous pharmaceutical composition of claim 1, wherein the adalimumab in the aqueous pharmaceutical composition has a protein unfolding temperature greater than or equal to 70.degree. C. 7. The aqueous pharmaceutical composition of claim 1, wherein the composition comprises the adalimumab, the acetate buffering agent or acetate buffer system, and the sugar stabilizer sucrose in a molar ratio of 1:14-40:288-865 respectively. 8. The aqueous pharmaceutical composition of claim 1, wherein the composition comprises the adalimumab, the acetate buffering agent or acetate buffer system, and the sugar stabilizer sucrose in a weight ratio of 25-75:0.12-3.0:15-140 respectively. 9. The aqueous pharmaceutical composition of claim 1, wherein the composition consists of: (a) 50 mg/mL adalimumab; (b) 10 mM acetate buffering agent or acetate buffer system; (c) 250-300 mM sucrose; (d) 1 mg/mL polysorbate 80; and (e) water; wherein the composition has a pH of pH 5.2.

Details for Patent 10,426,832

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2034-05-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2034-05-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2034-05-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014		2034-05-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015		2034-05-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	03/09/2016		2034-05-23